Shares of Pennsylvania-based Baudax Bio were up more than 40 percent after the company announced that the pain medication Anjeso was greenlit by the U.S. Food and Drug Administration.

The U.S. Food and Drug Administration’s busy schedule for drug reviews includes six supplemental BLAs for Merck’s blockbuster oncology brand Keytruda.